Open Access Peer-reviewed Research Article

Main Article Content

Xinghua Zhao corresponding author
Jiaojiao Zhang
Yutong Liang
Jie Li
Shi Ding
Yang Wang
Ye Chen
Ju Liu


Purpose: A simple, sensitive and specific HPLC–MS/MS method was established to analysis the pharmacokinetics of CB1107 in mouses. Methods: A simple, selective, and sensitive high-throughput liquid chromatography-tandem mass spectrometry (LC-MS-MS) method has been developed and validated for quantitative determination of CB1107 in rat serum.Chromatographic separation was achieved on a Zorbax Extend C18 Rapid Resolution HD column (4.6 mm × 50 mm, 1.8 μm). The column temperature was maintained at 35℃ and at flow rate of 0.6 mL/min. Injection volume was 20 μL. The mobile phases consisted of 0.1% formic acid in water (mobile phase A)and 0.1% formic acid in acetonitrile (mobile phase B), and total run time was 30min. MS-MS detection was performed in the selected monitoring mode of electrospray positive ionization reaction. Results: The pharmacokinetic characteristics of CB1107 in mice belong to the two-compartment model.When the doses were 400 mg/kg, 600 mg/kg and 800 mg/kg, corresponding area under the plasma concentration-time curve (AUC) respectively were 20.011±1.24 mg/h/L, 26.778±2.19 mg/h/L, 38.82±1.44 mg/h/L, suggesting that CB1107 have a good absorption in the body.And the AUC of three doses are proportional, indicating that CB1107 conforms to linear pharmacokinetics in vivo. Conclusion: This method was successfully applied to study the pharmacokinetics at three different doses of CB1107 after oral administration in mouses. In this study, the bioactivity mechanism of CB1107, by the pharmacokinetic investigation of CB1107 in vivo.

chronic myelogenous leukemia, Cyclobentinib (CB1107), pharmacokinetics

Article Details

Supporting Agencies
This work was supported by the Science and technology plan project of Shenyang (Grant No. 18-006-9-02).
How to Cite
Zhao, X., Zhang, J., Liang, Y., Li, J., Ding, S., Wang, Y., Chen, Y., & Liu, J. (2021). Pharmacokinetics study of potential anti-CML drug Cyclobentinib (CB1107) by HPLC–MS/MS. Journal of Pharmaceutical and Biopharmaceutical Research, 3(1), 169-175.


  1. Yang MJ, Xi QM, Jia WQ, et al. Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants. Bioorganic & medicinal chemistry letters, 29(24): 126758.
  2. Douxfils J, Haguet H, Mullier F, et al. Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis. Jama Oncology, 2016, 2(5): 625-632..
  3. Wang CM, Lin GT, Wang Z, et al. Determination of Imatinib in Rat Plasma by HPLC and Study of Its Pharmacokinetics. Journal of Chinese Pharmaceutical Sciences, 2013, 48(4): 293-296. https://doi.org10.11669/cpj.2013.04.012
  4. O’Hare T. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 2004, 104(8): 2532-2539.
  5. Jacquel A. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. The FASEB Journal, 2003, 17(14): 2160-2162.
  6. Cui J, Fu R, Zhou LH, et al. BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorganic & Medicinal Chemistry Letters, 2013, 23(8): 2442-2450.
  7. Weisberg E, Catley L, Wright RD, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias. Blood, 2007, 109(5): 2112-2120.
  8. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 2001, 20(36): 5054-5058.
  9. Illmer M, Schaich U, Platzbecker J, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia,2004, 18(3): 401-408.
  10. Soverini S, De BC, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the secondgeneration tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer, 2014, 120: 1002-1009.
  11. Hofmann WK, Komor M, Wassmann B, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood, 2003, 102: 659-661
  12. Yun SM, Jung KH, Kim SJ, et al. HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer letters, 2014, 348(1-2): 50-60.
  13. Ouyang Z, Qing-Feng DU, Liu XL, et al. Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment. Journal of Southern Medical University, 2008, 28(5): 704-706.
  14. Pagnano KBB, Bendit I, Boquimpani C, et al. BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. Cancer Investigation, 2015, 33(9): 1-8.
  15. Zhou ZJ, Wang Y, Li J, et al. Design, synthesis, and biological evaluation of Cyclobentinib (CB1107) as a potential anti-CML agent. Medicinal Chemistry Research, 2018, 27: 1863-1875.